Related Experiment Video

Updated: Jul 4, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Hereditary breast cancer: new genetic developments, new therapeutic avenues

Philippe M Campeau1, William D Foulkes, Marc D Tischkowitz

  • 1Department of Medical Genetics, McGill University Health Centre, McGill University, Montreal, QC, Canada. philippe.campeau@mail.mcgill.ca

Human Genetics
|June 26, 2008
PubMed

Insights

High-risk breast cancer genes like BRCA1/2 are crucial for DNA repair and targeted therapies. Understanding these genetic factors improves risk identification and develops new therapeutic strategies.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Six genes (BRCA1/2, TP53, PTEN, STK11, CDH1) are strongly associated with high breast cancer risk.
  • BRCA1 and BRCA2 genes are vital for DNA repair, making BRCA1/2-deficient tumors targets for PARP inhibitors.
  • Additional genes (ATM, CHEK2, PALB2, BRIP1) and lower-penetrance alleles (FGFR2) also increase breast cancer susceptibility.

Purpose of the Study:

  • To review recent findings on the function of key breast cancer susceptibility genes.
  • To discuss current and potential drug-targeting strategies for these genes.
  • To enhance understanding of breast cancer genetics for improved risk assessment and novel therapies.

Main Methods:

  • Literature review of recent scientific findings.
  • Analysis of gene functions and their roles in DNA repair and cancer development.
  • Discussion of therapeutic strategies targeting identified genes.

Main Results:

  • BRCA1/2 genes play critical roles in DNA repair, offering therapeutic targets like PARP inhibitors.
  • Various genes contribute to breast cancer risk, with different penetrance levels.
  • Insights into gene function facilitate the development of targeted therapeutic approaches.

Conclusions:

  • Understanding breast cancer susceptibility genes is key to identifying at-risk families.
  • Targeting specific gene functions offers promising avenues for developing precise therapeutic strategies.
  • Further research into these genetic factors will advance breast cancer prevention and treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...